Trial
NCT05208177
A Study of SHR-1802 in Patients With Advanced Solid Tumor
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Jiangsu HengRui Medicine Co., Ltd.
Collaborators
—
Condition
Advanced Solid Tumor
Intervention
SHR-1802＋camrelizumab + famitinib
Why stopped
Adjustment of R\&D strategy
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-08-22